EUCTR2016-004368-21-IT进行中（未招募）1 期
Phase II study on TSR-042 in advanced clear cells sarcoma - ACCeSs
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.The patient or legal representative must be able to read and understand the informed consent form (ICF) and must have been willing to give written informed consent for the trial. The subject may also provide an optional consent for the biological/translational sub-study associated. However, the subject may participate in the main trial without participating in biological/translational sub-study
- •2.Histological centrally and molecularly (ie the presence of translocation t(12;22)(q13;q12) confirmed diagnosis of clear cell sarcoma
- •3.Confirmed availability of archived FFPE tumor tissue block, or a minimum of 15 slides. If archived FFPE tissue is not available, then a de novo (ie, fresh) tumor sample must be obtained in accordance with local institutional practice for tumor biopsies
- •4.Locally advanced disease (i.e. surgical resection of local disease unfeasible radically, or unaccepted by the patient, or amenable to become less demolitive, or feasible, or easier, after cytoreduction) and/or metastatic disease
- •5.Have measurable disease based on RECIST 1.1 as determined by the site. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- •6.Patient can be naive or previously treated with 1 or 2 systemic regimens given for recurrent and/or metastatic disease
- •7.Eastern Cooperative Oncology Group (ECOG) Performance Status = 2
- •8.Adequate bone marrow function
- •9.Adequate organ function
- •10.Cardiac ejection fraction =50% as measured by echocardiogram
- •11.= 18 years of age on day of signing informed consent.
- •12.Female participant has a negative serum pregnancy test within 7 days prior to taking study treatment if of childbearing potential and agrees use an adequate method of contraception from screening through 150 days after the last dose of study treatment, or is of non childbearing potential
- •13.Participant must agree to not breastfeed during the study for 150 days after the last dose of study treatment.
- •14.Male participant agrees to use an adequate method of contraception (see Section 4.4 for a list of acceptable birth control methods) starting with the first dose of study treatment through 150 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
- •15. No history of arterial and/or venous thromboembolic event within the previous 12 months.
- •16.Participant receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy.
- •17.Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 21
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Participant must not be simultaneously enrolled in any interventional clinical trial
- •2.Previous treatment with any non-investigational agents within 14 days of first day of study drug dosing.
- •3.Must not have received investigational therapy = 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy
- •4.Other primary malignancy with <5 years clinically assessed disease-free interval, except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged to entail a low risk of relapse
- •5.Previous treatment with radiation therapy within 14 days of first day of study drug dosing, or patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- •6.Has known active central nervous system (CNS) metastases, leptomeningeal metastases, and/or carcinomatous meningitis.
- •7.Has active, non-infectious pneumonia
- •8.Has an active infection requiring systemic therapy
- •9.Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agents
- •10.Has received a live vaccine within 30 days of planned start of study therapy
- •11.Major surgery within 3 weeks prior to study entry. Participant must have recovered from any surgical effects.
- •12.Any one of the following currently or in the previous 6 months:
- •a.Myocardial infarction,
- •b.congenital long QT syndrome,
- •c.Torsades de Pointes,
- •d.arrhythmias (including sustained ventricular tachyarrhythmia and ventricular fibrillation, bradycardia defined as <50 bpm),
- •e.right bundle branch block and left anterior hemiblock
- •f.unstable angina
- •g.coronary/peripheral artery bypass graft,
- •h.symptomatic congestive heart failure CHF New York Heart Association Class III or IV), cerebrovascular accident, or transient ischemic attack
- •i.symptomatic pulmonary embolism.
- •13.Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=3, atrial fibrillation of any grade,or QTcF interval >470 msec at screening (average of triplicate ECG).
- •14.Severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, chronic obstructive pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord compression, psychiatric disorder that prohibits obtaining informed consent or active uncontrolled infection).
- •15.Patient experienced = Grade 3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities.
- •16.Participant has a diagnosis of immunodeficiency or has receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy
- •17.Any known active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (eg, hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected)
- •18.Any known history of human immunodeficiency virus
- •19.Subjects who have current active hepatic or biliary disease
- •20.Expected non-compliance to medical regimens
- •21.Known history of interstitial lung disease
- •22.Active autoimmune disease that has required systemic treatment in the past 2 years
- •23.Known severe hypersensitivity reactions to monoclonal antibodies (including TSR-042 components or excipients), any history of anaphylaxis, or uncontrolled asthma
研究者
相似试验
终止
2 期
Study on TSR-042 in Advanced Clear Cell SarcomaSarcoma, Clear CellNCT04274023Italian Sarcoma Group3
进行中（未招募）
1 期
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDSMyelodysplastic SyndromesAcute Myeloid LeukemiaNCT05457010Arcellx, Inc.24
已完成
2 期
Multicenter phase I/IIa study using T-cell receptor gene therapy in metastatic melanomamaligne melanomauveal melanoma1003005410040900skin cancerNL-OMON47165ederlands Kanker Instituut20
招募中
不适用
This is a multicentric study in which metastatic melanoma patients that have already been treated with at least 2 therapies, will be treated with their own white blood cells that are genetically transduced.metastasized melanomagemetastaseerde huidkankerNL-OMON28054KI-AV25
招募中
1 期
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 ExpressionSolid Tumor, AdultColorectal CancerNon Small Cell Lung CancerNSCLC, RecurrentNon-Small Cell Squamous Lung CancerPancreas CancerColorectal AdenocarcinomaRectal CancerOvarian NeoplasmsCancerOvarian CancerColon CancerMesotheliomaMesothelioma, MalignantOvary CancerMESOMLung CancerNSCLCCRCPancreatic NeoplasmNCT06051695A2 Biotherapeutics Inc.474